<DOC>
	<DOCNO>NCT01319253</DOCNO>
	<brief_summary>This pilot study inhale antibiotic regimen pilot study examine clinical laboratory endpoint patient inhale antibiotic treatment . We hypothesize alternation therapy utilize Cayston Tobi inhibit antibiotic resistance alternation therapy result decrease incidence antibiotic resistance Cystic Fibrosis ( CF ) microbial isolates . The long term strategic goal develop model biometric system select patient 's optimal inhale antibiotic regimen utilize clinical microbiological parameter .</brief_summary>
	<brief_title>A Comparator Study Evaluating Microbiological Resistance Effects Alternating Inhaled Antibiotic Therapies</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>&gt; = 6 year age Documentation Cf diagnosis History PA present sputum , least one occasion , 12 month prior Visit 1 . Currently inhale antibiotic regiment Must able provide write informed consent assent prior study related procedure Ability expectorate sputum Ability ro perform reproducible pulmonary function test Administration IV oral antipseudomonal antibiotic within 28 day prior Visit 1 Any serious active medical psychiatric illness , opinion investigator , woud interfere participant treatment , assessment , compliance protocol Current enrollment interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
</DOC>